BIO Submits Comments to FDA on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application
March 14, 2017
BIO submitted comments on the Food and Drug Administration’s draft guidance, Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Revised Draft Guidance for Industry.
BIO is committed to the effort to protect patients when biological products are handled in a manner that is inconsistent with their approved labeling and could result in contamination or a lack of effectiveness. BIO supports the FDA's efforts to release this draft guidance.
However, BIO believes some issues with respect to mixed, diluted, and repackaged biologics are not appropriately addressed in draft guidance or would benefit from additional clarification or refinement – such as the criticality of ensuring the sterility of the biological product’s primary container closure and its secondary packaging, which is essential to patient safety.
Download Full Comments Below
2017-3-14-17 BIO Comments On Revised Compounding Outside BLA FINAL
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
BIO submitted comments on the Food and Drug Administration’s draft guidance, Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application; Revised Draft Guidance for Industry.
BIO is committed to the effort to protect patients when biological products are handled in a manner that is inconsistent with their approved labeling and could result in contamination or a lack of effectiveness. BIO supports the FDA's efforts to release this draft guidance.
However, BIO believes some issues with respect to mixed, diluted, and repackaged biologics are not appropriately addressed in draft guidance or would benefit from additional clarification or refinement – such as the criticality of ensuring the sterility of the biological product’s primary container closure and its secondary packaging, which is essential to patient safety.